Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ritonavir on JNJ-61393215 PK
NCT03593954Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rocavorexant in major depressive disorder (MDD), anxiety disorders and panic disorder, sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Day 5, Last Quantifiable Plasma Concentration at Day 5 and 5 more. Started Jul 2018; status: completed.
02
Drugs
rocavorexant
03
Conditions
major depressive disorder (MDD)anxiety disorderspanic disorder
Beyond the preview
Go deeper on NCT03593954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03593954.